Literature DB >> 3436262

The possible role of quinolones in yersiniosis.

J A Hoogkamp-Korstanje1.   

Abstract

The in vitro susceptibility of 135 strains of Yersinia enterocolitica was tested by agar dilution. About 85% of the strains were susceptible to trimethoprim (1 mg/L), tetracycline (4 mg/L), chloramphenicol (4 mg/L) and cefuroxime (8 mg/L); 90 to 100% to piperacillin (16 mg/L), cefotaxime (8 mg/L) and gentamicin (1 mg/L); 100% to ciprofloxacin (less than or equal to 0.016 mg/L), ofloxacin (0.06 mg/L) and pefloxacin (0.12 mg/L). The outcome of 88 patients, treated for various forms of yersiniosis, showed 15% failure for trimethoprim or co-trimoxazole and tetracycline and 70% failure for cephalosporins and aminoglycoside-beta-lactam combinations. Four patients were successfully treated with ciprofloxacin 500 mg orally or 300 mg intravenously administered twice daily for up to 6 weeks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436262     DOI: 10.2165/00003495-198700341-00029

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  Incidence of human infection with Yersinia enterocolitica serotypes O3, O8, and O9 and the use of indirect immunofluorescence in diagnosis.

Authors:  J A Hoogkamp-Korstanje; J de Koning; J P Samsom
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

2.  Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.

Authors:  J A Hoogkamp-Korstanje; H J van Oort; J J Schipper; T van der Wal
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

3.  The susceptibility of Yersinia to eleven antimicrobials.

Authors:  F Soriano; J Vega
Journal:  J Antimicrob Chemother       Date:  1982-12       Impact factor: 5.790

4.  In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.

Authors:  J A Hoogkamp-Korstanje; C A Meijer
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

5.  Atypical Yersinia enterocolitica: clinical and epidemiological parameters.

Authors:  E J Bottone
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948

6.  Yersinia enterocolitica pharyngitis.

Authors:  C O Tacket; B R Davis; G P Carter; J F Randolph; M L Cohen
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

7.  Yersinia enterocolitica: guidelines for serologic diagnosis of human infections.

Authors:  E J Bottone; D J Sheehan
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

8.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

  8 in total
  4 in total

1.  In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus.

Authors:  J A Frean; L Arntzen; T Capper; A Bryskier; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

Review 2.  Yersinia enterocolitica endocarditis: case report and literature review.

Authors:  H Giamarellou; A Antoniadou; K Kanavos; C Papaioannou; S Kanatakis; K Papadaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

3.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 4.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.